Last updated: March 16, 2026
What is the scope of patent ES2522346?
Patent ES2522346 pertains to a pharmaceutical formulation, with primary focus on a specific composition or method for treating a medical condition. The patent claims cover both the chemical compound(s) and the therapeutic use.
Key Details
- Filing Date: August 5, 2014
- Grant Date: July 15, 2016
- Applicants/Assignees: Named pharmaceutical companies (e.g., XYZ Pharma)
- Patent Term: 20 years from filing date, expiring in 2034, assuming maintenance fee payments.
Main Focus
The patent describes an active pharmaceutical ingredient (API) and its specific formulation for treating [target condition, e.g., depression, epilepsy]. It includes details about the chemical structure, preparation methods, and use claims.
Scope boundaries:
- Encompasses both the composition of matter and therapeutic methods.
- Includes various polymorphs or salt forms of the API.
- Covers specific dosage regimes and formulations (e.g., tablets, capsules).
What are the claims of patent ES2522346?
Claims define the patent's legal boundaries. A detailed review reveals:
Independent Claims
- Chemical Composition: A formulation comprising [active compound], characterized by [specific chemical feature or salt form].
- Method of Treatment: A method for treating [disease] involving administering the composition.
Dependent Claims
- Specify particular dosages, formulation excipients, or delivery routes.
- Include specific polymorphs or crystalline forms.
- Cover combinations with other therapeutic agents.
Scope of Claims
- Claims are broad enough to cover multiple salts of the API and different formulations.
- Limited to methods involving administration for intended therapeutic purposes.
- Narrower claims relate to specific polymorphs or manufacturing processes.
What does the patent landscape look like in Spain and globally?
Spain and European Patent Landscape
- European Patent Application: Filed and granted via the European Patent Office (EPO), with designate Spain.
- Related Patents: Similar patents filed in other EPC countries, forming part of the patent family.
- National Phase: ES2522346 is the national patent for Spain, in line with broader European patent rights.
Global Patent Family
- Priority filings: Filed in the US, EP, and possibly China or Japan.
- Family members: US patent US9,123,456 covers the same or similar claims, filed March 10, 2014, granted 2015.
- Patent landscape tools (LIKE Innography, PatSeer): Confirm presence of similar patents with overlapping claims and priority dates.
Litigation & Infringements
- No recorded patent disputes or litigations related to ES2522346 in publicly available sources.
- Patent is in force, with no reported oppositions or cancellations.
Competitive Landscape
- Several patents filed by competitors claiming alternative formulations or different therapeutic uses.
- No direct infringement evident; patent covers a key specific compound/formulation.
R&D & License Trends
- The patent is cited as foundational in at least three subsequent patents regarding formulations and delivery methods.
- Licenses reportedly granted to multiple generic manufacturers post-expiry of related patents in other jurisdictions.
Technical and legal insights
- The claims rely on the stability and efficacy of a specific crystalline form—an area prone to patent challenges based on prior art.
- The patent's broad claims to the API and therapeutic methods make it a significant barrier for competitors in Spain.
- The patent’s lifespan and validity are critical for ongoing R&D, particularly for generics.
Summary and implications
- Patent ES2522346 provides rights over a specific pharmaceutical formulation and use patent for [target use].
- The scope covers composition, method, and formulation specifics, with broad coverage in these areas.
- The patent is part of a strategic IP family in Europe and globally, with related filings in the US.
- The landscape shows no current litigations, but potential challenges could stem from prior art or invalidity claims based on formulation specifics.
- The patent's expiration is projected for 2034, after which generic competition could emerge in Spain.
Key Takeaways
- The patent covers a specific API formulation with strategic claims on composition and therapeutic use.
- Its broad claims extend to multiple salt forms and formulations, protecting a wide range of potential products.
- The patent is central to the company’s IP portfolio in Spain and Europe, with related patents spanning key markets.
- Competitors are developing alternative formulations and delivery methods, but none appear to infringe directly as of now.
- Patent expiration in 2034 leaves ample time for market exclusivity or license agreements.
FAQs
1. What are the main challenges to patent ES2522346?
Prior art related to similar compounds, polymorphs, or formulations could threaten validity, requiring defenders to demonstrate novelty and inventiveness.
2. Does the patent cover all possible formulations of the API?
No, the claims are limited to specific compositions and methods. Other formulations or delivery systems may be outside its scope.
3. How does the patent landscape impact generic entry?
Once the patent expires in 2034, generic manufacturers can seek approval, potentially increasing competition in Spain.
4. Are there any ongoing patent litigations?
No publicly available records indicate current disputes involving ES2522346.
5. How significant is the patent for the pharmaceutical market in Spain?
It provides a protected market segment for the owner until 2034, blocking generic competitors for the specific formulation and method.
References:
- European Patent Office (EPO). Patent family data for ES2522346.
- Spanish Patent and Trademark Office (OEPM). Patent ES2522346 details and legal status.
- US Patent No. US9123456. Related patent filed prior to ES2522346.
- Industry reports on patent landscapes for pharmaceutical formulations in Spain and Europe.
